Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Legend Biotech ( (LEGN) ) has issued an announcement.
On October 10, 2025, Legend Biotech announced that the U.S. FDA approved a label update for its CARVYKTI® CAR-T cell therapy to include overall survival data from the Phase 3 CARTITUDE-4 study. This update highlights a significant improvement in overall survival for patients with relapsed, refractory multiple myeloma compared to standard care. Additionally, the label now includes warnings about immune effector cell-associated enterocolitis and the reactivation of the John Cunningham virus, which can lead to serious complications, emphasizing the need for careful management by prescribing physicians.
The most recent analyst rating on (LEGN) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall stock score is driven by its financial performance challenges, including ongoing losses and cash flow issues. Despite positive sentiment from the earnings call and strategic growth initiatives, the stock’s bearish technical indicators and negative valuation metrics weigh heavily on its score. The company’s future prospects hinge on achieving operational efficiency and profitability.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is known for its CAR-T cell therapy products, particularly targeting multiple myeloma.
Average Trading Volume: 1,238,530
Technical Sentiment Signal: Sell
Current Market Cap: $5.85B
Learn more about LEGN stock on TipRanks’ Stock Analysis page.